Kevin Ali bought $299k of OGN
Chief Executive Officer at Organon & Co.. 34,000 shares at an average of $8.81, traded May 5, 2025, filed May 6, 2025.
Score components
- +25RoleCEO
- +14Trade size$299k at market
- +3Relative to holdingsHoldings up 14%
- +18Price context0% above the 52-week low; 57% below the 52-week high
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001821825-25-000025, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 5, 2025 | POpen-market purchase Common Stock | +34,000 | $8.81 | $299k | 282,731 | May 6, 2025 |
Related signals
Other insiders at Organon & Co. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | OGNbuy Organon & Co. | Carrie Smith Cox Executive Chair | $502k 65,400 shares | +525% | |
| 66Notable | Organon & Co. | Carrie Smith Cox Executive Chair | $101k 12,469 shares | - | |
| 58Moderate | Organon & Co. | Aaron Falcione Chief Human Resources Officer | $48k 5,500 shares | +10% | |
| 56Moderate | Organon & Co. | Daniel Karp Executive VP, Corp. Dev. | $29k 3,500 shares | +8% | |
| 59Moderate | Organon & Co. | Kirke Weaver Gen. Counsel & Corp. Secy. | $74k 8,045 shares | +18% | |
| 68Notable | Organon & Co. | Matthew M Walsh Chief Financial Officer | $101k 11,400 shares | +9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.